for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Seagen Inc

SGEN.O

Latest Trade

162.51USD

Change

1.17(+0.73%)

Volume

699,784

Today's Range

159.09

 - 

162.80

52 Week Range

133.20

 - 

213.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
161.34
Open
160.98
Volume
699,784
3M AVG Volume
15.35
Today's High
162.80
Today's Low
159.09
52 Week High
213.94
52 Week Low
133.20
Shares Out (MIL)
181.93
Market Cap (MIL)
29,353.31
Forward P/E
-69.86
Dividend (Yield %)
--

Next Event

Q3 2021 Seagen Inc Earnings Release

Latest Developments

More

Seagen And RemeGen Announce Exclusive Worldwide License And Co-Development Agreement For Disitamab Vedotin

Seagen Reports Q2 Loss Per Share Of $0.47

Seagen Inc - On July 11, Entered Into A Commercial Supply Agreement Dated As Of July 1, 2021 With Hovione

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Seagen Inc

Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.

Industry

Biotechnology & Drugs

Contact Info

21823 30Th Drive Se, Suite

BOTHELL, WA

98021

United States

+1.425.5274000

https://www.seagen.com/

Executive Leadership

Clay B. Siegall

Chairman of the Board, President, Chief Executive Officer

Todd E. Simpson

Chief Financial Officer

Jean I. Liu

Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary

Chip Romp

Executive Vice President - Commercial U.S.

Vaughn B. Himes

Chief Technical Officer

Key Stats

2.16 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.7K

2019

0.9K

2020

2.2K

2021(E)

1.5K
EPS (USD)

2018

-1.410

2019

-0.960

2020

3.370

2021(E)

-2.309
Price To Earnings (TTM)
49.51
Price To Sales (TTM)
12.32
Price To Book (MRQ)
8.65
Price To Cash Flow (TTM)
44.51
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
22.12
Return on Equity (TTM)
19.53

Latest News

Latest News

Merck to buy $1 bln stake in Seattle Genetics, co-develop cancer therapy

Drugmaker Merck & Co Inc would buy $1 billion worth of equity stake in Seattle Genetics's common stock, the companies said on Monday.

Merck to buy $1 billion equity stake in Seattle Genetics

Merck & Co Inc said on Monday it would buy $1 billion worth of equity stake in Seattle Genetics's common stock.

BRIEF-Seattle Genetics Announces Positive Topline Results From Phase 2 Clinical Trial Of Tisotumab Vedotin

* SEATTLE GENETICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF TISOTUMAB VEDOTIN IN RECURRENT OR METASTATIC CERVICAL CANCER

BRIEF-Genmab Announces Favorable Topline Results From Phase 2 Clinical Trial Of Tisotumab Vedotin

* REG-GENMAB ANNOUNCES VERY FAVORABLE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF TISOTUMAB VEDOTIN IN RECURRENT OR METASTATIC CERVICAL CANCER

BRIEF-Seattle Genetics Announces Initiation Of Phase 1 Clinical Trials For Two Novel Antibody-Based Drug Candidates

* SEATTLE GENETICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIALS FOR TWO NOVEL ANTIBODY-BASED DRUG CANDIDATES

BRIEF-Seattle Genetics Announces Positive Results From Exploratory Analyses Of Her2climb For Tukysa

* SEATTLE GENETICS ANNOUNCES POSITIVE RESULTS FROM EXPLORATORY ANALYSES OF HER2CLIMB FOR TUKYSA™ (TUCATINIB) IN BRAIN METASTASES PATIENTS WITH HER2-POSITIVE BREAST CANCER

BRIEF-Seattle Genetics Says Adcetris Receives European Commission Approval For Treatment Of Adult Patients With Previously Untreated Systemic Anaplastic Large Cell Lymphoma

* SEATTLE GENETICS ANNOUNCES ADCETRIS® (BRENTUXIMAB VEDOTIN) RECEIVES EUROPEAN COMMISSION APPROVAL FOR TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com...

BRIEF-Seattle Genetics Highlights Data From Expanding Oncology Portfolio During Virtual Scientific Program Of 2020 ASCO Annual Meeting

* SEATTLE GENETICS HIGHLIGHTS DATA FROM EXPANDING ONCOLOGY PORTFOLIO DURING VIRTUAL SCIENTIFIC PROGRAM OF THE 2020 ASCO ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Seattle Genetics Announces Approval Of Tukysa (Tucatinib) In Switzerland For Treatment Of Patients With Metastatic Her2-Positive Breast Cancer

* SEATTLE GENETICS ANNOUNCES APPROVAL OF TUKYSA™ (TUCATINIB) IN SWITZERLAND FOR TREATMENT OF PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER Source text for Eikon: Further company coverage:

Seattle Genetics wins early U.S. approval for $18,500 breast cancer therapy

Seattle Genetics Inc's add-on therapy for an advanced form of breast cancer that has progressed despite prior treatment was on Friday approved months ahead of schedule by the U.S. Food and Drug Administration.

Seattle Genetics wins early U.S. approval for $18,500 breast cancer therapy

Seattle Genetics Inc's add-on therapy for a type of breast cancer that has progressed despite prior treatments has won earlier-than-expected approval, the U.S. Food and Drug Administration said on Friday.

BRIEF-Seattle Genetics Announces Potential Accelerated Approval Pathway In The U.S. For Padcev™

* SEATTLE GENETICS ANNOUNCES POTENTIAL ACCELERATED APPROVAL PATHWAY IN THE U.S. FOR PADCEV™ (ENFORTUMAB VEDOTIN-EJFV) IN COMBINATION WITH IMMUNE THERAPY PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR ADVANCED UROTHELIAL CANCER

BRIEF-Seattle Genetics Announces Cancellation Of Presentation And Webcast At The Cowen 40th Annual Healthcare Conference

* SEATTLE GENETICS ANNOUNCES CANCELLATION OF PRESENTATION AND WEBCAST AT THE COWEN 40TH ANNUAL HEALTHCARE CONFERENCE

BRIEF-Five Prime Therapeutics Licenses Antibodies To Seattle Genetics For Use In Novel Antibody Drug Conjugate Programs

* FIVE PRIME THERAPEUTICS LICENSES ANTIBODIES TO SEATTLE GENETICS FOR USE IN NOVEL ANTIBODY DRUG CONJUGATE (ADC) PROGRAMS

BRIEF-Seattle Genetics Says FDA Accepts Priority Review Of Tucatinib New Drug Application

* SEATTLE GENETICS ANNOUNCES FDA FILING ACCEPTANCE FOR PRIORITY REVIEW OF TUCATINIB NEW DRUG APPLICATION (NDA) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER

BRIEF-Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response

* SEATTLE GENETICS AND ASTELLAS ANNOUNCE UPDATED RESULTS FROM PHASE 1B/2 TRIAL OF PADCEV™ (ENFORTUMAB VEDOTIN-EJFV) IN COMBINATION WITH IMMUNE THERAPY PEMBROLIZUMAB AS INVESTIGATIONAL FIRST-LINE TREATMENT FOR ADVANCED BLADDER CANCER

BRIEF-Seattle Genetics Reports Q4 Earnings Per Share Of $0.14

* SEATTLE GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Seattle Genetics Posts Q4 Loss Per Share Of $0.14

* SEATTLE GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

FDA grants accelerated approval for Astellas, Seattle Genetics' bladder cancer drug

(This December 18 story corrects third paragraph to remove reference to Padcev being the first FDA approved drug for advanced or metastatic urothelial cancer)

Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up